Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
News|Slideshows|February 21, 2019
Diabetes Drugs and Cardioprotection: 8 Questions on Key Trials
Author(s)Grace Halsey
Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.
Advertisement
Advertisement
Related to this article
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.
A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
3
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
4
Sentinel Antibodies May Identify Patients With Blunted Vaccine Responses
5